1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Lazaros Lekakis: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). Mosunetuzumab, Polatuzumab, CAR-T Cell Therapy - Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Recruiting | Lazaros Lekakis | 22 | 2022-12-14 | 2025-12-31 |
Immunotherapy, Adoptive (1) · polatuzumab vedotin (1)
United States (1)